Just in time for Thanksgiving, our CEO, Dr.?Robert Ang, has published the next article in his series, “Finding Joy in Work,” which focuses on why "good enough" is sometimes okay and the importance of appreciating our work and practicing rest in a holistic way.??Also, you will learn about his rather unique hobby!
Vor Bio
生物技术研究
Cambridge，Massachusetts 13,734 位关注者
Vor Bio's vision is to cure blood cancers through cell and genome engineering.
关于我们
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
- 网站
-
https://www.vorbio.com
Vor Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
地点
-
主要
获取路线
100 Cambridgepark Dr
Suite 101
US，Massachusetts，Cambridge，02140
Vor Bio员工
动态
-
November is National Marrow Awareness Month. This month and year-round, we honor the bone marrow donors who give cancer patients the invaluable gift of a second chance at life and recognize that many patients still face barriers in accessing treatment, including underrepresented populations who are unable to find a matched donor. Learn how you can become a bone marrow donor by visiting NMDP: https://www.nmdp.org/
-
At #VorBio, we aim to cure Acute Myeloid Leukemia (AML) with our novel approach combining a shielded transplant and targeted therapies, such as an antibody drug conjugate or a CAR-T. Listen as our CEO, Dr. Robert Ang, explains the challenge with treating AML and how Vor’s approach could provide a new treatment for this devastating disease.?
-
Looking forward to contributing to this important conversation hosted by the Alliance for Regenerative Medicine and Catalent Pharma Solutions because the therapies we are developing are only valuable if we can effectively get them into the hands of the patients who need them most.
Happening today - Commercial Strategies for Cell and Gene Therapies ??? ?? 11:00am - 12:00pm ET Join ARM and Catalent Pharma Solutions for our last Building the Future of Regenerative Medicine webinar of the year. This live webinar will discuss the critical steps required to successfully bring cell and gene therapies to market. Register here to tune in: https://lnkd.in/gEG8xKXe Moderator: Delara Motlagh Ph.D. Vice President, Global Cell Therapy and Plasmid DNA, Catalent Pharma Solutions Featured Speakers: Rob Allen, Ph.D. Managing Partner and General Manager Europe, Dark Horse Consulting Group Inc. Sarah Creviston Global Vice President, Patient Advocacy and Public Affairs, Novartis Gene Therapies John King Chief Commercial Officer and Head of Business Development, Vor Bio Kristin Yarema, Ph.D. President and CEO, Poseida Therapeutics, Inc.
-
-
We recognized Transgender Awareness Week at #VorBio by partnering with Greater Boston PFLAG to host a panel of speakers who shared their experiences of transgender advocacy and navigating careers as a transgender person. A huge thank you to PFLAG, Dani Chase, Elijah Oyenuga, and Tate Duffy, MA, DEIJL for speaking with our team about your experience and how we can support the transgender community.
-
Next week, #VorBio President & CEO, Dr, Robert Ang and CFO Han Choi, M.D., LL.M., will discuss our novel approach for treating #AML in a Fireside Chat at the Stifel Institutional 2024 Healthcare Conference. View the webcast at:?https://lnkd.in/e_Sn85pn.
-
We are thrilled to announce that #VorBio has been named a BioSpace 2025 #BestPlacestoWork winner! We are thankful for each one of our #Voracians for sharing their passion, fellowship, and humility and making Vor Bio a welcoming, fun, and meaningful place to work.
-
-
On #VeteransDay, we honor and thank veterans especially our colleagues at #VorBio for their service to our country.
-
Today, we announced our Q3 results and provided a corporate update. Read our press release here:?https://lnkd.in/efhEyHzs.
-
We are excited to be in Houston at #SITC2024 this week where Voracian Anne Campbell will present research on our next generation, genome-engineered CAR-T platform with the potential to improve CAR safety, potency, and sensitivity to cancer antigens.?View the poster here:?https://lnkd.in/e3mvWpvz.